BA DPhil CChem FRSC
I took early retirement from GSK in 2019 and set up Blue Burgundy Ltd. My 30+ years of drug discovery experience provide expertise in identifying issues and opportunities in discovery programmes, which enable my imaginative and innovative thinking to address the unique needs of every programme.
I joined Wellcome in 1990, following BA/DPhil at the University of Oxford and Post Doc at Ben May Institute, University of Chicago. Subsequent career navigated changes, mergers, and acquisitions, charting significant contributions to six development candidates in antivirals (HIV/HBV/Herpes), iNOS and Factor Xa. Moved to early stage discovery in 2006, contributing to and leading numerous successful H2L programs (HTS/Fragments/ELT).
Amongst many fruitful partnerships in international collaborations (France, Italy, Japan, Korea, USA), productive links with GSK Diseases of the Developing World group in Spain were a highlight (influential leadership in several programmes and served on SAB for EU-funded ORCHID TB consortium).